Australia sets a new course for prostate cancer detection

Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early detection of prostate cancer, with the release of the 2026 Clinical Practice Guidelines.

Replacing the 2016 Guidelines, the new recommendations establish a national framework for risk assessment, PSA testing and diagnostic pathways aimed at detecting prostate cancer earlier while reducing unnecessary testing and treatment.

Developed by the Prostate Cancer Foundation of Australia (PCFA) in partnership with Cancer Council Australia, the Guidelines were funded by a $770,000 grant from the Federal Government. To support its implementation, which was approved by the National Health and Medical Research Council (NHMRC), the government is providing $320,000 to the Royal Australian College of General Practitioners (RACGP) to develop an education and awareness program for doctors.

Professor Jeff Dunn AO, Chair of the Guideline Steering Committee and PCFA’s Chief of Mission and Head of Research, said the new Guidelines represented a watershed moment in the nation’s approach to prostate cancer.

“Much has changed over the past decade. The evidence has matured, diagnostic technologies have advanced, and clinical practice has evolved substantially,” said Professor Dunn. “For the first time, Australia now has a contemporary national framework that better balances the benefits of detecting aggressive prostate cancer early with the need to minimise unnecessary harms.”

The updated recommendations reflect significant advances in the evidence base since the previous Guidelines were published in 2016. In particular, long-term follow-up from the European Randomised Study of Screening for Prostate Cancer (ERSPC), has strengthened the recommendation to offer PSA testing every two years to men aged 50-69. It shows a reduction of 13% in prostate cancer deaths following additional longitudinal data.

“Our ambition is to ensure every Australian man has access to the very best evidence available, giving him the greatest possible opportunity to detect clinically significant prostate cancer early, receive timely treatment where required, and ultimately reduce his risk of dying from this disease,” Professor Dunn added.

One of the most significant changes since the 2016 Guidelines is the role of multiparametric MRI (mpMRI), which is now standard practice in Australia before biopsy. The technology can help avoid unnecessary immediate biopsies following elevated PSA levels, reducing biopsies by up to 50%, while reliably detecting clinically significant cancers.

Adjunct Professor Peter Heathcote, Chair of the Guideline Expert Advisory Panel, said advances in diagnosis had fundamentally changed the way clinicians investigate prostate cancer.

“Modern prostate cancer diagnosis is no longer based on a PSA blood test alone,” stated Professor Heathcote. “Today’s diagnostic pathway incorporates individual risk assessment, shared decision-making, multiparametric MRI before biopsy, targeted biopsy techniques, and active surveillance for men with low-risk disease. These advances allow clinicians to identify clinically significant cancers more accurately while reducing unnecessary biopsies, significantly reducing risks of overtreatment, and ensuring we protect men’s quality of life while managing individual risks.”

Prostate cancer is Australia’s most commonly diagnosed cancer, with almost 29,000 Australian men expected to be diagnosed this year and almost 4,000 expected to die from the disease.

The Guidelines also strengthen and update recommendations for men with a significant family history, inherited genetic risk and other groups at increased risk of developing clinically significant prostate cancer.

For PCFA CEO Anne Savage, publication of the Guidelines marks the beginning of the next challenge.

“Developing world-class Guidelines is only half the task. Now we must ensure they are implemented,” explained Savage. “Evidence only saves lives when it reaches the men who need it. Australian men need to understand their individual risk, know when to have the conversation with their GP, and be supported by clinicians with access to the latest evidence.”

“If we get implementation right, future generations of Australian men will look back on these Guidelines as the moment Australia fundamentally changed its approach to prostate cancer early detection,” she added.

The scale of the disease burden highlights the importance of effective implementation. Nearly 300,000 Australian men are alive today after a diagnosis of prostate cancer, with high numbers continuing treatment. The disease contributes to health expenditure of more than $1.6 billion each year, including more than $500 million on the Pharmaceutical Benefits Scheme (PBS).

Dan Repacholi MP, Australia’s first Special Envoy for Men’s Health, said “As co-chair of the government’s Prostate Cancer Expert Advisory Group which was established in March, I am committed to better detection, treatment, and care for Australian men with prostate cancer. I encourage any bloke aged 45 or more to have a chat with their doctor about whether they are at higher risk of prostate cancer and need to be tested.”

The Guidelines are the product of an extensive evidence-review and consultation process. Over two years, the Guideline Steering Committee convened by PCFA examined more than 27,000 scientific abstracts, evaluated more than 1,100 published research papers and considered more than 1,400 submissions received through three rounds of public consultation.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.